Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
about
Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK CellsNatural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyTailoring the Treatment of Melanoma: Implications for Personalized MedicineAdvantages and applications of CAR-expressing natural killer cellsUtilizing chimeric antigen receptors to direct natural killer cell activityChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityGenetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptorThe Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.Engineering Chimeric Antigen Receptors.Engineering Natural Killer Cells for Cancer Immunotherapy.Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells.
P2860
Q26751020-661064C6-1B0B-4F12-8136-5C717855F4C7Q26771449-EFF6C626-2414-440D-B6DE-16235F34C43AQ26775806-4164C191-B46B-480E-8B3F-83CADF6C7F67Q28080875-AF148DDD-C988-410E-9D8C-059CD5E1C856Q28082868-32B59E61-D8F2-4F22-BA95-309D08A8E2C8Q33700795-828C661C-B608-4E2C-9F6E-C7AB58E2C28CQ35711209-1B09D415-80B9-431B-8112-A6A67DDED752Q37376346-EFFC529C-8039-4B99-A7EC-04B423161BD9Q37434176-ACF16626-FA2A-4C69-A1D8-CAA1A54919DCQ38670431-6A009730-937F-4E73-916A-A844EE68C3BEQ38928938-6F8C0AEF-9FEA-4514-A9D5-AC90A6736F8BQ39276909-FB6ABFF5-5B36-4B77-91BA-F145045A9281Q39408704-C8B13E22-4111-4D25-878A-A50A904CEE12Q47843897-6504D370-5197-41E4-91C3-C9FD0E0544D9Q55129555-A182385A-00B9-4D37-BB9E-83985C5FEBFB
P2860
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@en
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@nl
type
label
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@en
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@nl
prefLabel
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@en
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@nl
P2093
P2860
P356
P1476
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.
@en
P2093
Changzhen Liu
Ganlin Zhang
Huamin Han
Rongzhi Liu
Shenghua Li
P2860
P304
P356
10.1038/ICB.2013.45
P577
2013-10-08T00:00:00Z